The Food and Drug Administration's Oncologic Drugs Advisory Committee is scheduled to review Cell Therapeutics Inc.'s (CTIC) New Drug Application for Pixantrone for the treatment of relapsed and refractory non-Hodgkin's lymphoma on February 10.
The company began a rolling New Drug Application submission for Pixantrone to the FDA in April 2009 and completed the submission in June 2009. The NDA submission was based on a phase III single-agent Pixantrone trial dubbed EXTEND, or PIX 301 in patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines.
The FDA is expected to make a final decision on Pixantrone on April 23.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.